期刊文献+

全自动二维液相色谱法测定腹腔感染患者血清中替加环素的浓度 被引量:8

Establishment of a 2D-LC-UV Method for the Determination of Tigecycline in Human Serum and Its Clinical Application
下载PDF
导出
摘要 目的:建立全自动二维色谱法(2D-LC-UV)测定血清中替加环素浓度,用于腹腔感染患者替加环素药物浓度的监测。方法:150μL样品进样,在一维柱ASTON C8(100 mm×4.6 mm,5μL)上初步分离,通过中间柱ASTON SCX(20 mm×4.6 mm,5μm)截取保留并在二维柱Agilent Extent-C18(150 mm×4.6 mm,5μm)上进一步分离,直至最终测定。一维柱流动相为30 mmol·L^(-1)磷酸二氢钠-乙腈-甲醇(40∶30∶30,p H=5.4);中间柱流动相为纯水;二维柱流动相为30 mmol·L^(-1)磷酸二氢钠-乙腈(75∶25,p H=3.5),流速均为1.0 m L·min^(-1),柱温40℃,检测波长244 nm。采集40名腹腔感染患者静滴替加环素(首剂量100 mg,维持剂量50 mg q12h)血清样本,测定峰浓度、中浓度、谷浓度,并估算AUC值。结果:本色谱条件下,替加环素与各杂质分离良好,线性范围0.03~30μg·mL^(-1),最低检测限10 ng·mL^(-1)。40名腹腔感染患者平均血清峰浓度(1.60±0.77)μg·mL^(-1),中浓度(0.84±0.36)μg·mL^(-1),谷浓度(0.57±0.25)μg·mL^(-1),估算平均AUC值(22.66±9.77)μg·h·mL^(-1)。结论:此法操作简单,准确、精密度好,适用于替加环素浓度-药效研究及临床监测。 Objective: In this study, tigecycline, a new glycylcycline antimicrobial agent was quantifiedby a two-dimensional liquid chromatography coupled with ultraviolet detection (2D- LC -UV). Methods: Inthis setup, two reversed phase liquid chromatography columns, ASTON C8 (100mm×4.6mm, 5 pm) and AgilentExtent-Ct8 (150mm×4.6mm, 5μm), were used as the first and second separation dimensions, respectively.An ASTON SCX (20 mm×4.6 mm, 5 pm) column was used as the connector to transfer the eluent from thefirst dimensional column to the second one for further separation. The mobile phases of the two dimensionsconsisted of 3 0 mmol.L-1-acetonitrile-methanol NaH〗PO4 (40:30:30, v/v , pH=5.4) and acetonitrile- 3 0 mmol.L-1NaH2PO4 (75:25, v/v , pH=3.5), respectively. The flow rates were both 1 mL-min-1 and the detection wavelengthwas 244 nm. Serum peak, middle and trough concentration samples from 40 patients with intra-abdominalinfections administrated with tigecycline (50 mg q12h) were analyzed and values of area undercurve (AUC) were estimated. Results: The calibration curves were linear over the range of 0.03-30 μg·mL_1.The average serum peak, middle and trough concentrations were (1.60±0.77) μg·m L-1, (0.84±0.36) μg·mL-1and (0.57±0.25)μg·mL-1, respectively. And the estimated AUC values were (22.66±9.77)μg·h -mL-1. Conclusions:This method can be used effectively in clinic and research fields.
出处 《药学与临床研究》 2016年第4期305-307,共3页 Pharmaceutical and Clinical Research
关键词 替加环素 血清浓度 腹腔感染 AUC Tigecycline Serum concentration Abdominal infection Area under curve
  • 相关文献

参考文献1

二级参考文献10

  • 1Lee LS,Kinzig-Schippers M,Nafziger AN,et al.Comparisonof 30-min and 3-h infusion regimens for imipenem/cilastatin and formeropenem evaluated by Monte Carlo simulation[J].Diagn Micro-biol Infect Dis,2010,68(3):251-258.
  • 2Li C,Kuti JL,Nightingale CH,et al.Population pharmacoki-netic analysis and dosing regimen optimization of meropenem inadult patients[J].J Clin Pharmacol,2006,46(10):1171-1178.
  • 3Zhou QT,He B,Zhang C,et al.Pharmacokinetics and pharma-codynamics of meropenem in elderly chinese with lower respira-tory tract infections:population pharmacokinetics analysis usingnonlinear mixed-effects modelling and clinical pharmacodynamicsstudy[J].Drugs Aging,2011,28(11):903-912.
  • 4Lee DG,Choi SM,Shin WS,et al.Population pharmacokineticsof meropenem in febrile neutropenic patients in Korea[J].Int J Anti-microb Agents,2006,28(4):333-339.
  • 5Doh K,Woo H,Hur J,et al.Population pharmacokinetics ofmeropenem in burn patients[J].J Antimicrob Chemother,2010,65(11):2428-2435.
  • 6Du X,Li C,Kuti JL,et al.Population pharmacokinetics andpharmacodynamics of meropenem in pediatric patients[J].J ClinPharmacol,2006,46(1):69-75.
  • 7Yoshizawa K,Ikawa K,Ikeda K,et al.Optimisation of imipe-nem regimens in patients with impaired renal function by pharmaco-kinetic-pharmacodynamic target attainment analysis of plasma andurinary concentration data[J].Int J Antimicrob Agents,2012,40(5):427-433.
  • 8Sakka S G,Glauner A K,Bulitta J B,et al.Population phar-macokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in arandomized,controlled trial[J].Antimicrob Agents Chemother,2007,51(9):3304-3310.
  • 9Dailly E,Kergueris M F,Pannier M,et al.Population pharma-cokinetics of imipenem in burn patients[J].Fundam Clin Pharma-col,2003,17(6):645-650.
  • 10Leelarasamee A,Rongrungruang Y,Trakulsomboon S,et al.Bioequivalence,antibacterial activity and therapeutic outcome of ageneric meropenem(Mapenem)[J].J Med Assoc Thai,2008,91(7):980-988.

共引文献14

同被引文献62

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部